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Effects of Intravenous Atrial Natriuretic
Peptide on Cardiac Sympathetic Nerve
Activity and Left Ventricular Remodeling in
Patients With First Anterior Acute Myocardial Infarction
Shu Kasama, MD,* Takuji Toyama, MD,* Takashi Hatori, MD,* Hiroyuki Sumino, MD,*
Hisao Kumakura, MD,† Yoshiaki Takayama, MD,† Shuichi Ichikawa, MD,† Tadashi Suzuki, MD,*
Masahiko Kurabayashi, MD*
Maebashi and Gunma, Japan
Objectives We sought to evaluate the effects of atrial natriuretic peptide (ANP) on cardiac sympathetic nerve activity
(CSNA) and left ventricular (LV) remodeling in patients with first anterior acute myocardial infarction (AMI) after
primary coronary angioplasty.
Background The activation of the renin-angiotensin-aldosterone system (RAAS) prevents the uptake of norepinephrine in the
myocardium. Atrial natriuretic peptide, a circulating hormone of cardiac origin, has vasodilatory and diuretic
properties, and can inhibit the RAAS.
Methods We studied 50 patients with first anterior AMI who were randomly assigned to receive ANP (group A) or isosor-
bide dinitrate (group B) before and after primary coronary angioplasty. The ANP or ISDN was continuously in-
fused 48 h. The extent score (ES) was determined from 99mTc-pyrophosphate scintigraphy to evaluate the area
of initial myocardial damage 3 to 5 days after primary angioplasty. The LV end-diastolic volume (LVEDV) and LV
ejection fraction (LVEF) were determined by left ventriculography 2 weeks later. The delayed heart/mediastinum
count (H/M) ratio, delayed total defect score (TDS), and washout rate (WR) were determined from 123I-meta-
iodobenzylguanidine scintigraphy after 3 weeks.
Results After primary angioplasty, age, gender, risk factors, peak serum creatine phosphokinase concentration, recanalization
time, and ES were similar in the 2 groups. However, in group A (n 25), the TDS was significantly lower (34 8 vs.
41  8; p  0.05), the H/M ratio was significantly higher (1.96 0.18 vs. 1.74  0.23; p  0.05), and the WR was
significantly lower (35  8% vs. 44  12%; p  0.005) than in group B (n  25). Moreover, the LVEDV and LVEF in
group A were better than in group B (LVEDV: 85.5 28.5 ml vs. 106.3  39.4 ml [p  0.05]; LVEF: 47.9  10.2%
vs. 41.5  11.8% [p  0.05]).
Conclusions Intravenous ANP improves CSNA and prevents LV remodeling in patients with first anterior AMI. (J Am Coll
Cardiol 2007;49:667–74) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.09.048p
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avent-free survival after acute myocardial infarction (AMI)
s influenced by the extent of residual myocardial ischemia
1) and the global left ventricular (LV) ejection fraction
LVEF) (2). Patients with LV dysfunction are more likely
o have progressive LV dilation, which is an independent
eterminant of long-term survival (3). Moreover, activation
f the sympathetic nervous system is one of the cardinal
rom the *Department of Cardiovascular Medicine, Gunma University School of
edicine, Maebashi, Japan; and the †Department of Internal Medicine, Cardiovas-
ular Hospital of Central Japan, Gunma, Japan.a
Manuscript received April 24, 2006; revised manuscript received August 22, 2006,
ccepted September 18, 2006.athophysiologic abnormalities associated with the failing
uman heart (4). Therefore, plasma norepinephrine con-
entrations affect the morbidity and mortality in patients
ith AMI (5).
In the acute phase of AMI, nitroglycerin has been
eported to have a favorable effect in preventing LV remod-
ling (6). However, this agent may stimulate the renin-
ngiotensin-aldosterone system (RAAS) despite its benefi-
ial hemodynamic effect (7). In contrast, atrial natriuretic
eptide (ANP) has a wide range of potent biologic effects,
ncluding natriuretic, diuretic, and vasodilatory properties
nd inhibition of the RAAS (8). The efficacy of intravenous
dministration of ANP in patients with acute myocardial
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ANP and Cardiac Sympathetic Nerve Activity February 13, 2007:667–74infarction has been reported pre-
viously (9). In that report, the
intravenous administration of
ANP prevented LV dilation and
remodeling after primary coro-
nary angioplasty in patients with
AMI.
Myocardial imaging with 123I-
meta-iodobenzylguanidine (123I-
MIBG), an analog of norepi-
nephrine, is useful for detecting
abnormalities in the myocardial
adrenergic nervous system in pa-
tients with AMI (10). Myocar-
dial ischemic area and cardiac
123I-MIBG defect size are corre-
lated in patients undergoing
reperfusion therapy for acute cor-
onary syndromes (11). Many re-
ports have suggested that inhibi-
tion of the RAAS can improve
cardiac sympathetic nerve activity,
based on cardiac 123I-MIBG scin-
tigraphic studies, in patients with
heart disease (12–20). However,
o reports discuss the changes in cardiac 123I-MIBG scinti-
raphic findings in response to ANP administration in patients
ith AMI, although we previously reported improved cardiac
ympathetic nerve activity (CSNA) in patients with nonisch-
mic decompensated acute heart failure (17).
ethods
atients. From April 2003 through February 2006, 66
atients who were admitted to the Coronary Care Unit
CCU) of our institution for their first myocardial infarction
f the anterior wall and showed Thrombolysis In Myocar-
ial Infarction (TIMI) flow grade 0 or 1 (21) at initial
oronary angiography were considered as the study popula-
ion. The diagnosis of AMI was made on the basis of chest
ain of30 min duration, ST-segment elevation of2 mm
n 2 contiguous electrocardiographic (ECG) leads and more
han threefold increase in serum creatine phosphokinase
ctivities. Patients were excluded from the study for the
ollowing reasons: cardiogenic shock or hypotension, de-
ned as systolic blood pressure 80 mm Hg (3 patients
ere excluded); prior myocardial infarction (4 patients);
ultivessel disease (5 patients); and need for mechanical
upport (intra-aortic balloon pumping, mechanical ventila-
ion, or both) (4 patients). Therefore, this report is based on
he remaining 50 patients. All patients underwent percuta-
eous coronary intervention (PCI) and achieved successful
oronary reflow (TIMI flow grade 2 or 3) within 6 hours
fter the symptom onset. The study was approved by the
thics review board of our institution, and informed written
Abbreviations
and Acronyms
123I-MIBG 
123I-meta-iodobenzylguanidine
99mTc-PYP 
99mTc-pyrophosphate
AMI  acute myocardial
infarction
ANP  atrial natriuretic
peptide
ES  extent score
H/M  heart/mediastinum
count
ISDN  isosorbide dinitrate
LV  left ventricular
LVEDP  left ventricular
end-diastolic pressure
LVEDV  left ventricular
end-diastolic volume
LVEF  left ventricular
ejection fraction
TDS  total defect score
WR  washout rateonsent was obtained from all patients. atudy protocol. This is a prospective randomized study
double-blind, 1:1 ratio). After establishing a diagnosis of
MI, we randomly assigned the patients to receive either
NP (group A; n  25) or isosorbide dinitrate (ISDN)
group B; n 25). After the patient arrived in the CCU and
emodynamic stability was assured, ANP was continuously
nfused at 0.025 g/kg/min in group A, and ISDN was
ontinuously infused at 0.67 g/kg/min in group B. After
he start of ANP or ISDN continuous infusions, all patients
nderwent cardiac catheterization with the femoral ap-
roach after an injection of 100 U/kg of heparin. The
nfarct-related artery was visualized in five views with contrast
njections, and patency was determined according to the TIMI
lassification. Patients who had persistent occlusion of the
nfarct-related vessel (TIMI flow grade 0 or 1) underwent PCI
tandard techniques.
Data on additional electrocardiographic ST-segment
levation and reperfusion arrhythmias were collected at
he time of reperfusion. The following arrhythmias not
bserved before reperfusion were regarded as reperfusion
rrhythmias: accelerated idioventricular or atrioventricu-
ar junctional rhythms, ventricular tachycardia (at least 3
onsecutive beats), and ventricular fibrillation.
After angioplasty, ANP or ISDN was continuously infused
48 h. All patients received oral aspirin and ticlopidine.
oreover, oral angiotensin-converting enzyme inhibitors, an-
iotensin receptor blockers, beta-adrenergic blocking agents,
nd/or diuretics were added and continued.
We performed resting 201Tl and 99mTc-pyrophosphate
PYP) dual single-photon emission computed tomography
SPECT) imaging to evaluate the area of initial myocardial
amage 3 to 5 days after primary angioplasty. Follow-up
oronary angiography and left ventriculography (right ante-
ior oblique 30°) were performed 2 weeks after angioplasty.
t our institution, follow-up catheterization is routinely
erformed 2 weeks after angioplasty in patients with AMI.
eft ventricular end-diastolic pressure (LVEDP) was deter-
ined from a transducer connected to a pig-tail catheter just
efore left ventriculography. The left ventricular end-
iastolic volume (LVEDV) and LVEF were calculated by
he area-length method. These measurements were per-
ormed by an independent observer in a blinded manner.
he 123I-MIBG scintigraphy was performed 3 weeks later.
ardiac 123I-MIBG scintigraphy. The method of 123I-
IBG imaging has been described previously (14–20).
riefly, the 123I-MIBG was obtained from a commercial
ource (Daiichi Radioisotope Laboratories, Tokyo, Japan).
t 15 min and at 4 h after injection, the anterior planar and
PECT images were obtained with a single-head gamma
amera (Millennium MPR, GE Medical Systems, Waukesha,
isconsin).
The heart/mediastinum count (H/M) ratio was deter-
ined from the anterior planar delayed 123I-MIBG
mage. The washout rate (WR) was calculated from early
nd delayed planar images. Regional tracer uptake was
ssessed semiquantitatively using a 5-point scoring system
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February 13, 2007:667–74 ANP and Cardiac Sympathetic Nerve Activity0  normal to 4  no uptake) in 17 segments of delayed
PECT image, as recommended by the American Heart
ssociation (22). The total defect score (TDS) was calcu-
ated as the sum of all defect scores.
esting 201Tl and 99mTc-PYP dual SPECT. The method
f 201Tl and 99mTc-PYP dual SPECT has been described
reviously (23). In brief, each patient received 740 MBq of
9mTc-PYP intravenously and then 74 MBq of 201Tl 2 h
ater. Fifteen minutes after the 201Tl injection, all patients
nderwent myocardial imaging with dual SPECT with the
ame system. For each patient, these images were divided
nto 17 segments by the same method used for 123I-MIBG
maging. We evaluated the myocardial perfusion SPECT
bnormalities of 201Tl by using the TDS calculated by the
ame method. Furthermore, the extent score (ES) was
etermined from 99mTc-PYP as the sum of the area of
bnormal uptake for all 17 segments.
tatistical analysis. Statistical analysis was performed by
sing SPSS 12.0 for Windows (SPSS Inc., Chicago,
llinois). Numerical results are expressed as mean  SD.
omparison of baseline categoric data between the 2 groups
as done by the chi-square test, and differences between
ontinuous variables were evaluated using the unpaired
test. The reperfusion phenomenon of additional electro-
ardiographic ST-segment elevation and reperfusion ar-
hythmias were expressed as percentages and compared by
isher exact test. A value of p  0.05 was considered to be
tatistically significant.
esults
linical characteristics. No significant differences were
bserved in clinical characteristics between the subjects in
he 2 groups on entry into the study. Age, gender, recana-
ization time, and peak creatine phosphokinase levels in the
cute phase were similar for both groups (Table 1). The
ean duration of ANP administration was 56  15 h
range 48 to 96 h) in group A, and that of ISDN
dministration was 59  16 h (range 48 to 96 h) in group
. There were also no differences in the in-hospital medi-
ations between the 2 groups. The mean dose of enalapril
as 8.2  2.8 mg/day in group A versus 8.5  3.0 mg/day
n group B (p NS). The mean dose of perindopril was 2.6
1.2 mg/day in group A versus 2.5  1.4 mg/day in group
(p  NS). The mean dose of valsartan was 104  54
g/day in group A versus 93  55 mg/day in group B (p 
S). The mean dose of carvedilol was 12  5 mg/day in
roup A versus 11  4 mg/day in group B (p  NS). The
ean dose of furosemide was 30  12 mg/day in group A
ersus 31  14 mg/day in group B (p  NS). Finally, the
ose of spironolactone was only 25 mg/day in both groups.
ther in-hospital therapies and clinical follow-up were
imilar in both groups.
omparison of reperfusion phenomenon. The incidence
f additional electrocardiographic ST-segment elevation in
roup A was significantly lower than in group B (20% vs. g5%; p  0.05), and that of reperfusion arrhythmias in
roup A was also lower than in group B (28% vs. 48%; p 
.05).
omparison of cardiac 201Tl and 99mTc-PYP dual
PECT. Table 1 provides a summary of the ES and TDS
ata for both groups as evaluated by cardiac 201Tl and
9mTc-PYP dual SPECT. From this dual SPECT, we
onfirmed that all patients had first anterior AMI, and there
ere no patients with prior myocardial infarction. The ES
valuated from 99mTc-PYP was similar in both groups.
owever, the TDS of 201Tl in group A was significantly
ower than in group B (p  0.01).
omparison of left ventricular parameters 2 weeks after
reatment. Table 1 presents a summary of LVEDP,
VEDV, and LVEF determined during heart catheteriza-
ion. Two weeks after treatment, LVEDV was significantly
ower and LVEF was significantly higher in group A than in
roup B (both: p 0.05). However, LVEDP was similar in
oth groups.
omparison of cardiac 123I-MIBG scintigraphic findings
weeks after treatment. The TDS, H/M ratio, and WR
re shown in Figure 1. The TDS in group A was signifi-
antly lower than in group B (p  0.05). The H/M ratio in
linical Characteristics and LVarameters of Patient in Both Groups
Table 1 Clinical Characteristics and LVParameters of Patients in Both Groups
Group A
(n  25)
Group B
(n  25) p Value
Age (yrs) 61 12 62 13 0.78
Gender
Male 20 (80.0%) 19 (76.0%) 0.73
Female 5 (20.0%) 6 (24.0%) 0.73
History of stroke 2 (8.0%) 1 (4.0%) 0.55
Diabetes mellitus 7 (28.0%) 6 (24.0%) 0.74
Hypertension 14 (56.0%) 13 (52.0%) 0.77
Hyperlipidemia 8 (32.0%) 9 (36.0%) 0.77
Current smoker 14 (56.0%) 15 (60.0%) 0.77
Recanalization time (h) 3.7 1.5 3.9 1.8 0.67
TIMI flow grade 3 23 (92.0%) 23 (92.0%) 1.00
TIMI flow grade 2 2 (8.0%) 2 (8.0%) 1.00
Stent 23 (92.0%) 22 (88.0%) 0.64
Peak CPK (IU/l) 2,959 1,648 3,187 1,891 0.65
In-hospital medications
ACE inhibitor 23 (92.0%) 23 (92.0%) 1.00
ARB 5 (20.0%) 6 (24.0%) 0.73
Beta-blocker 21 (84.0%) 22 (88.0%) 0.68
Loop diuretics 5 (20.0%) 6 (20.0%) 0.73
Spironolactone 2 (8.0%) 2 (8.0%) 1.00
Extent score of 99mTc-PYP 9 3 9 4 1.00
Total defect score of T1-201 27 7 32 6 0.01
LVEDP (mm Hg) 11.2 4.3 12.1 6.8 0.58
LVEDV (ml) 85.5 28.5 106.3 39.4 0.05
LVEF (%) 47.9 10.2 41.5 11.8 0.05
ata are presented as the mean value  SD.
ACE  angiotensin-converting enzyme; ARB  angiotensin receptor blocker; CPK  creatine
hosphokinase; LVEDP  left ventricular end-diastolic pressure; LVEDV  left ventricular end-
iastolic volume; LVEF  left ventricular ejection fraction; TIMI  Thrombolysis In Myocardial
nfarction; 99mTc-PYP  99mTc-pyrophosphate.roup A was significantly higher than in group B (p 
0
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ANP and Cardiac Sympathetic Nerve Activity February 13, 2007:667–74.05). Finally, the WR in group A was significantly lower
han in group B (p  0.005).
Representative 123I-MIBG images for both groups 3
eeks after reperfusion therapy are shown in Figures 2
nd 3.
iscussion
ur findings demonstrate for the first time that intravenous
dministration of ANP could improve cardiac sympathetic
erve activity and prevent left ventricular remodeling to a
arger extent compared with ISDN after reperfusion therapy
n patients with first anterior AMI.
Reperfusion of the ischemic myocardium by PCI reduces
he size of the infarct and improves LV function, both of
hich contribute to an improved clinical outcome for
atients with AMI (24,25). However, in some patients who
ndergo reperfusion therapy, reperfusion per se adversely
eads to tissue damage known as reperfusion injury (26).
ntravenous administration of ANP is a promising candi-
ate for an adjunctive therapy for AMI, because it can
uppress the RAAS and endothelin-1, both of which
odulate cardiac remodeling (9,27). On the other hand,
schemic preconditioning is a phenomenon in which brief
eriods of ischemia confer cardioprotective effects against
rolonged ischemia (28). Gross and Auchampach (29)
eported that ischemic preconditioning produces cardiopro-
ection via activation of adenosine triphosphate (ATP)-
ensitive potassium channels. Pharmacologic opening of the
hannel mimics ischemic preconditioning, whereas closing
he channel blocks cardioprotection (30). Atrial natriuretic
eptide is a known ATP-sensitive potassium channel acti-
ator (30); therefore, this agent may have ischemic precon-
itioning effect during ischemia reperfusion. Moreover, Das
t al. (31) have discussed that an ATP-sensitive potassium
hannel activator exhibits cardioprotective effects against
Figure 1 Comparison of Cardiac 123I-Meta-Iodobenzylguanidine
H/M  heart/mediastinum count; TDS  total defect score; WR  washout rate.eperfusion injury in the myocardium. In that report, celective activation of mitochondrial ATP-sensitive potas-
ium channels increased survival rate and decreased the
ncidence of arrhythmias. In the present study, the incidence
f additional electrocardiographic ST-segment elevation
nd reperfusion arrhythmias was lower in the ANP group
han in the ISDN group. Atrial natriuretic peptide may
herefore have cardioprotective effects against reperfusion
njury in patients with AMI.
Currently, nuclear imaging with 99mTc-PYP scintigraphy
s used to measure the area of initial myocardial damage
fter AMI (32,33). A significant correlation has been
eported between myocardial 99mTc-PYP scintigraphic up-
ake and the area at risk in cases of myocardial infarction
34). Because 201Tl scintigraphic uptake is known to indi-
ate restored myocardial perfusion and cell viability, 201Tl
nd 99mTc-PYP dual SPECT can be useful in identifying
he extent of damaged but salvaged myocardium (35). In our
tudy, the ES evaluated by 99mTc-PYP was similar in both
roups. Therefore, the initial area at risk of both groups in
his study may be similar. However, defect scores from 201Tl
cintigraphy were significantly lower in the ANP group than
n the ISDN group. From this, we concluded that intrave-
ous administration of ANP may increase the amount of
alvaged myocardium after reperfusion therapy in patients
ith AMI.
123I-meta-iodobenzylguanidine, an analog of the adren-
rgic neuron blocking agent guanethidine, is thought to use
he same mechanism of myocardial uptake and release as
orepinephrine (36). An association between myocardial
orepinephrine concentration and 123I-MIBG uptake in
atients has been reported previously (37). Therefore,
ardiac 123I-MIBG imaging may be a useful tool for
etecting abnormalities of the myocardial adrenergic ner-
ous system in patients with AMI (10). Miura et al. (38)
eported that the ischemic preconditioning effect attenuates
igraphic Findings 3 Weeks After Treatment
0.05 compared with group A; †p  0.005 compared with group A.Scint
*p ardiac sympathetic nerve injury during myocardial isch-
671JACC Vol. 49, No. 6, 2007 Kasama et al.
February 13, 2007:667–74 ANP and Cardiac Sympathetic Nerve ActivityFigure 2 Representative Single-Photon Emission Computerized Tomographic MIBG Images 3 Weeks After Treatment for Both Groups
ANP  atrial natriuretic peptide; HLA  horizontal long axis; ISDN  isosorbide dinitrate; MIBG  123I-meta-Iodobenzylguanidine; SA  short axis; VLA  vertical long axis.
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ANP and Cardiac Sympathetic Nerve Activity February 13, 2007:667–74mia, suggesting this effect may mediate increasing the
yocardial uptake of norepinephrine. However, there are
o reports on the changes in cardiac 123I-MIBG scinti-
raphic findings in response to ANP administration in
atients with AMI. In the present study, the TDS, H/M
atio, and WR determined by cardiac 123I-MIBG scintig-
aphy were better in the ANP group than in the ISDN
roup.
Buss et al. (39) reported that aldosterone directly prevents
yocardial uptake of norepinephrine in experimental ani-
al model. Moreover, in that study, the mineralocorticoid
eceptor antagonist spironolactone preserved cardiac norepi-
ephrine uptake in salt-sensitive Dahl rats (39). On the
ther hand, ANP has been reported to inhibit aldosterone
ynthase gene expression in cultured neonatal rat cardiocytes
40). Thus, ANP as well as spironolactone may improve
ardiac norepinephrine uptake in the failing human heart.
herefore, the present findings demonstrate for the first
ime that ANP could improve cardiac norepinephrine up-
ake evaluated by 123I-MIBG scintigraphy in patients with
MI. In the present study, because a small number of
atients were having spironolactone after AMI (2 patients
n each group) and the dose of this drug was similar in both
roups, it is unlikely that spironolactone influenced our
esults.
Hayashi et al. (9) reported that ANP treatment decreases
Figure 3 Representative Anterior Planar Delayed MIBG Images
In these 2 examples, delayed heart/mediastinum (H/M) count ratio and washout
respectively, for a patient from group A and 1.55 and 52%, respectively, for a patilasma aldosterone levels and suppresses increasing plasma nrain natriuretic peptide (BNP) concentrations after reper-
usion therapy in patients with AMI. Plasma aldosterone
nd BNP levels are well known as predictors of congestive
eart failure after myocardial infarction (41,42). Moreover,
23I-MIBG scintigraphic findings have useful prognostic
alue in the failing ischemic human heart (10). Therefore,
dministration of ANP may be effective for the reducing
ncidence of heart failure after AMI. In the future, we need
o evaluate comparative effects of ANP and ISDN on
ortality and morbidity in the patients with AMI of this
tudy.
tudy limitations. The small number of patients with
MI included in this study was a limitation. In addition,
he present study used a fixed ANP dose. Future studies
ust assess the dose-response effects of ANP on 123I-
IBG scintigraphic findings and LV parameters. In the
resent study, we did not perform Swan-Ganz catheteriza-
ion to measure hemodynamic parameters after treatment.
owever, LVEDP was similar in the 2 groups. We believe
hat hemodynamic status was similar in the 2 groups and
hat ANP improves cardiac sympathetic nerve activity in
atients with AMI. However, further studies will be re-
uired to confirm this hypothesis.
It has been reported that intravenous administration of
NP (nesiritide) decreases regional sympathetic nerve ac-
ivity in patients with coronary heart failure (43). Although
eeks After Treatment for Both Groups
re 2.01 and 36%,
m group B. Abbreviations as in Figure 2.3 W
rate we
ent froesiritide is used for patients with heart failure in other
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February 13, 2007:667–74 ANP and Cardiac Sympathetic Nerve Activityountries, it is not clinically used in Japan. Moreover,
ardiac 123I-MIBG scintigraphy has not yet achieved broad
linical acceptance. Therefore, it is still difficult to compare
he effects of intravenous administration of ANP and those
f BNP on cardiac sympathetic nerve activity in the failing
uman heart. We need to evaluate comparative effects of
NP and BNP on cardiac sympathetic nerve activity by
ardiac 123I-MIBG scintigraphy after reperfusion therapy in
MI patients in the future.
Recent clinical studies have suggested that stem cell therapy
an contribute to the regeneration of infarcted myocardium
nd enhance neovascularization of ischemic myocardium, re-
ulting in sustained improvement of cardiac function (44,45).
owever, stem cell therapy is generally expensive for clinical
se. Use of ANP is safer, more feasible, and less expensive
han stem cell therapy; therefore, we believe that adminis-
ration of ANP after reperfusion therapy in patients with
MI should be generally applicable.
onclusions. The TDS, H/M ratio, and WR as deter-
ined by cardiac 123I-MIBG scintigraphy were better in the
NP group than in the ISDN group. The ES determined
y 99mTc-PYP was similar in the 2 groups. Two weeks after
reatment, LV parameters were better in the ANP group
han in the ISDN group. These findings indicate that ANP
an benefit cardiac sympathetic nerve activity and LV
emodeling in patients with first anterior AMI.
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